Request Demo

MeMed BV

Now the only reason to treat a bacterial infection is because there actually is one!

In 15 minutes from a small sample, the FDA-cleared MeMed BV® computationally integrates the levels of three host immune proteins into a simple score indicating the likelihood of a bacterial immune response or co-infection versus a likely viral immune response.

Need a quick guide to the MeMed BV score?

What if you could tell bacterial from viral infections in 15 minutes?

See clinical benefits?

  • Minimize diagnostic uncertainty
  • Enhance patient care and outcomes
  • Improve treatment decision-making
  • Speed up response to infections

Improve antibiotic stewardship?

  • Support responsible antibiotic use
  • Potential to reduce unnecessary antibiotic prescriptions
  • Fight antibiotic resistance
  • Promote informed and effective treatment plans

Market differentiation and patient engagement

  • Boost patient satisfaction through advanced care
  • Increase retention by offering cutting-edge services
  • Drive demand with innovative diagnostic capabilities
  • Set your facility apart as a leader in healthcare technology
  • Strengthen trust and reputation in the healthcare community
Key - Convenience bg-memed-key

How does MeMed BV work?

MeMed BV Performance

MeMed BV performance

The FDA clinical study (Apollo) was conducted to establish the diagnostic performance of the MeMed BV test for differentiating bacterial from viral infection in patients with suspected acute bacterial or viral infection.1

MeMed BV performance independently confirmed in blinded validation and real-world evidence of >20,000 patients

Our unique emphasis on quality and breadth of clinical evidence sets MeMed apart. MeMed BV performance has been validated in multi-national, double-blind clinical studies and real world settings enrolling almost 20,000 subjects in Europe, Israel and the United States.1-11 These studies have consistently demonstrated compelling performance results in different clinical settings, age groups, and patients with different clinical syndromes.

 

chart

MeMed BV performance goals independently confirmed in unprecedented validation and real-world usage encompassing >20,000 patients.1-11

References

  1. MeMed data on file. Based on secondary endpoint analysis in Apollo Clinical Study (NCT04690569).
  2. Oved K, Cohen A, Boico O, Navon R, Friedman T, Etshtein L, et al. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PloS One. 2015 Mar 18;10(3):e0120012.
  3. van Houten CB, de Groot JA, Klein A, Srugo I, Chistyakov I, de Waal W, et al. A host-protein based assay to differentiate between bacterial and viral infections in preschool children (OPPORTUNITY): A double-blind, multicentre, validation study. Lancet Infect Dis. 2017 Apr 1;17(4):431-40.
  4. Srugo I, Klein A, Stein M, Golan-Shany O, Kerem N, Chistyakov I, et al. Validation of a novel assay to distinguish bacterial and viral infections. Pediatrics. 2017 Oct 1;140(4).
  5. Eden E, Srugo I, Gottlieb T, Navon R, Boico O, Cohen A, et al. Diagnostic accuracy of a TRAIL, IP-10 and CRP combination for discriminating bacterial and viral etiologies at the Emergency Department. J Infect. 2016 Aug 1;73(2):177-80.
  6. Mor M, Paz M, Amir L, Levy I, Scheuerman O, Livni G, et al. Bacterial vs viral etiology of fever: A prospective study of a host score for supporting etiologic accuracy of emergency department physicians. PLoS One. 2023 Jan 30;18(1):e0281018.
  7. Papan C, Argentiero A, Porwoll M, Hakim U, Farinelli E, Testa I, et al. A host signature based on TRAIL, IP-10, and CRP for reducing antibiotic overuse in children by differentiating bacterial from viral infections: A prospective, multicentre cohort study. Clin Microbiol Infect. 2022 May 1;28(5):723-30.
  8. Halabi S, Shiber S, Paz M, Gottlieb TM, Barash E, Navon R, et al. Host test based on TRAIL, IP-10 and CRP for differentiating bacterial and viral respiratory tract infections in adults: Diagnostic accuracy study. Clin Microbiol Infect. 2023 Jun 1.
  9. Chokkalla AK, Tam E, Liang R, Cruz AT, Devaraj S. Validation of a multi-analyte immunoassay for distinguishing bacterial vs. viral infections in a pediatric cohort. Clin Chim Acta. 2023 Jun 1;546:117387.
  10. Kalmovich B, Rahamim-Cohen D, Shapiro Ben David S. Impact on patient management of a novel host response test for distinguishing bacterial and viral infections: Real world evidence from the urgent care setting. Biomedicines. 2023 May 22;11(5):1498.
  11. Klein A, Shapira MA, Lipman-Arens S, Bamberger E, Srugo I, Chistyakov I, et al. Diagnostic accuracy of a real-time host-protein test for infection. Pediatrics. 2023 Dec 1;152(6):e2022060441.
*MeMed BV on venous whole blood is 510K cleared. Currently available only for the US market.